

NEWSLETTER Phase Holographic Imaging PHI AB (publ) Lund, June 4, 2018

New CEO commentary — "Redefining aging with HoloMonitor"

In the CEO commentary <u>"Redefining aging with HoloMonitor</u>" Peter Egelberg comments on the promising research results that were recently reported by Australian television. By studying primitive bacteria researchers at Queensland University of Technology in Australia have been able to develop a new drug that has the potential to dramatically slow the aging process. <u>The newscast</u> reports that by using the company's cell analyzer HoloMonitor the researchers were able to see how old and damaged cells became young.

About PHI

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Head-quartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.

For additional information, please contact:

Peter Egelberg, CEO Tel: +46 703 19 42 74 E-mail: <u>ir@phiab.se</u> Web: <u>www.phiab.se</u>